Professor Dalgleish is a specialist in identifying the properties of existing treatments and repurposing them for new clinical applications.
He is known for his work on enhancing the therapeutic properties of thalidomide to develop two new drugs, Lenalidomide and Pomalidomide, which are now both used for the treatment of multiple myeloma and lymphoma. For this pioneering work, Professor Dalgleish was awarded the Lederberg Prize by Celgene.
In recent work, Professor Dalgleish has demonstrated that a vaccine originally developed for TB (IMM-101) greatly enhances the immune response to cancers, either when given alone or in combination with chemotherapy or other immunotherapies. Unlike most other treatment, this method has no systemic toxicity.
Professor Dalgleish has reported that patients who do not respond to immunotherapy have high levels of inflammatory proteins. Combining anti-inflammatory agents with immunotherapy should enhance response rates. This may explain why Naltrexone, which he has reported as inhibiting the TLR-9 inflammatory marker, appears to benefit cancer patients.
Together with Dr Wai Liu, he has been exploring the potential of cannabinoid derivatives to treat cancer. They appear to enhance the beneficial effects of radiotherapy and chemotherapy without any additional toxicity.
Professor Dalgleish has been made a Visiting Professor at the Earle Chiles Research Institute, Portland, U.S.A. (Director: Bernard Fox).
Presentations and publications
Dalgleish AG. The Third Institute for Cancer Vaccines and Immunotherapy (ICVI) symposium on immunotherapy: May 12-13, 2017, Royal Society, London, UK. Cancer Immunol Immunother. 2018 Mar 2. doi: 10.1007/s00262-018-2137-9. PMID:29500634
Fusi A, Dalgleish A. The importance for immunoregulation for long-term cancer control. Future Oncol. 2017 Aug;13(18):1619-1632. doi: 10.2217/fon-2017-0085. Epub 2017 Aug 4. PMID:28776411
Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer. 2016 Oct 11. doi: 10.1038/bjc.2016.342. No abstract available. PMID:27727233
Cant R, Dalgleish AG, Allen RL. Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors. Front Immunol. 2017 Jul 11;8:809. doi: 10.3389/fimmu.2017.00809. PMID:28744288
Leeman H, Kaminska E, Green D, Bodman-Smith M, Gravett A, Bodman-Smith K, Copier J, Coulton G, Fusi A, Dalgleish AG. Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine. Transl Oncol. 2018 Dec 7;12(3):397-403. doi:10.1016/j.tranon.2018.11.002. [Epub ahead of print]PMID:30530187